Methenolone Enanthate
DHT-derived AAS with low androgenic profile; non-aromatizable
Mechanism of Action
Methenolone is a DHT derivative with 1-methyl and 2-oxo modifications, making it a non-aromatizable compound with one of the lowest androgenic profiles among AAS. The 1-methyl group reduces hepatic metabolism, enabling oral bioavailability (as methenolone acetate). The enanthate ester provides sustained intramuscular release. Methenolone binds AR with moderate affinity but exhibits high anabolic selectivity with minimal androgenic, estrogenic, or progestogenic activity. It does not cause water retention and has minimal impact on blood pressure, making it studied for lean tissue preservation.
Evidence Level
Clinical Trial - Human
12 studies published
Pharmacology
Molecular Weight
344.5 g/mol (free base); 414.6 g/mol (enanthate ester)
Half-Life
Approximately 10.5 days (enanthate ester, intramuscular)
Bioavailability
Near 100% via intramuscular injection; ~40% oral (as acetate)